{
    "nct_id": "NCT06603844",
    "official_title": "A Phase 1/2 Study to Investigate the Safety, Pharmacokinetics and Efficacy of CRB-601, a Monoclonal Antibody Against Integrin Avb8, in Patients with Advanced Solid Tumors",
    "inclusion_criteria": "* Confirmed diagnosis of select locally advanced or metastatic solid tumors that have progressed after at least one line of therapy or have no other standard therapy with proven clinical benefit available.\n* Measurable disease on imaging as assessed by RECIST 1.1 Eastern Cooperative Oncology Group (ECOG) performance status (PS) greater or equal to 2.\n* Life expectancy of more than 12 weeks.\n* Adequate hematologic and end-organ function.\nHealthy volunteers allowed\nMust have minimum age of 18 Years",
    "exclusion_criteria": "* History of solid tumor malignancies other than the disease under study within 3 years of study enrollment\n* History of and/or current cardiovascular events or conditions\n* Chronic severe liver disease or liver cirrhosis\n* Systemic autoimmune disease\n* Active thrombophlebitis, thromboembolism or hypercoagulability states or uncontrolled bleeding or diabetes.\n* Interstitial lung disease within 6 months of study enrollment.\n* Active or persistent infection\n* Other conditions that in the opinion of the Investigator would compromise the outcomes of the study.",
    "miscellaneous_criteria": ""
}